Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cellular Biomedicine Group, Inc.    CBMG


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Cellular Biomedicine Group : to Present at 5th Annual CAR-TCR Summit in Boston

share with twitter share with LinkedIn share with facebook
share via e-mail
09/09/2019 | 09:29am EST

NEW YORK and SHANGHAI, Sept. 9, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company will present at the upcoming Annual CAR-TCR Summit in Boston, MA September 10-13, 2019.

Cellular Biomedicine Group logo (PRNewsfoto/Cellular Biomedicine Group)

Wednesday, September 11, 2:47pm
Yihong Yao, PhD, Chief Scientific Officer
"Meeting the Challenge of Delivering Cell & Gene Therapy Products to Patients in China

  • Medical digitalization will fundamentally transform research, clinical, and healthcare as a whole
  • How China can advance the progress in novel therapy modalities
  • De-risking clinical trials by leveraging fast-track clinical studies

A copy of the presentation will be made available on the Company's website following the presentation.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. It's Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific, which partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) approved the Company's IND application for a Phase II trial for AlloJoin™, CBMG's "Off-the-Shelf" allogeneic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and has accepted the Company's IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including regulatory approval of our IND applications, our plan to configure part of our Shanghai facility with GE Healthcare's FlexFactory platform, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG's reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K and. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law. 

For more information, please contact:

Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com

Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1254 / 212-896-1267
Email: cellbiomed@kcsa.com 


View original content to download multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-present-at-5th-annual-car-tcr-summit-in-boston-300914055.html

SOURCE Cellular Biomedicine Group

© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
11/12CELLULAR BIOMEDICINE GROUP, INC. : Change in Directors or Principal Officers (fo..
11/12CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure, Financial Statement..
11/11CELLULAR BIOMEDICINE GROUP : Announces Receipt of a Preliminary Non-Binding "Goi..
11/08CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure (form 8-K)
11/06CELLULAR BIOMEDICINE : 3Q Earnings Snapshot
11/06CELLULAR BIOMEDICINE : CBMG Reports Q3 2019 Financial Results and Business Highl..
10/30CELLULAR BIOMEDICINE GROUP : to Report Third Quarter 2019 Results on November 6,..
10/17CELLULAR BIOMEDICINE GROUP, INC. : Change in Directors or Principal Officers (fo..
10/03CELLULAR BIOMEDICINE GROUP, INC. : Entry into a Material Definitive Agreement, O..
More news